We believe that Italy can become a strategic hub for innovation in the life sciences. This is why we are committed every day to attracting international investors and supporting entrepreneurial projects with high technological content.
The latest example of this journey is the establishment of KINZBIO Italia, which has launched the Phage Excellence Center “INPHACT – Institute for Phage Therapy and Advanced Countermeasures”: a unique initiative in Europe, designed as a concrete response to the global crisis of antimicrobial resistance (AMR). The Center will integrate cutting-edge research, biotechnological development, and GMP production in a One-Health infrastructure with an international vocation, with key objectives to:
- develop personalized phage-based therapies against resistant infections,
- propose sustainable alternatives to antibiotics in livestock farming,
- introduce biocontrol solutions for agriculture and the environment,
- strengthen research with proprietary AI-based software (Paku and Blinky) for the management and advanced analysis of genomic data.
With this project, KINZBIO Italia and its institutional partners are building a model that combines science, technology, and socio-economic impact, placing Italy at the center of a global challenge. We are proud to contribute to initiatives like this, which strengthen the national biotech ecosystem and attract international investors in a sector that is strategic for health, the environment, and the economy.
The Magnifica Consulting team serves as advisor to major international groups, supporting and guiding them in building the company, defining the project, and preparing dossiers for institutional engagement. Magnifica closely follows each project step by step, working alongside innovative startups, SMEs, and global leaders in the pharma, biotechnology, agritech, and energy sectors.